MetaCure is a medical device company dedicated to the development and commercialization of minimally invasive solutions for diabesity, arguably today’s most prevalent global epidemic.

MetaCure’s implantable medical device, TANTALUS, is based on an innovative technology that significantly reduces blood glucose levels by applying electrical stimulation to the stomach during meals.

The TANTALUS device has obtained marketing approval in the EU, and bears the CE Mark since 2006. MetaCure has a quality system in place and was certified for the EN ISO 13485 standard (quality system for medical devices) since 2003. The design and manufacturing processes of the TANTALUS system are subject to stringent standards for quality assurance in the field of medical devices.